Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials

Clinical Respiratory Journal

Volumn 7, Issue 4, 2013, Pages 305-318

  Cheng, Ting ^a   Gong, Yi ^b   Guo, Yi ^a   Cheng, Qijian ^a   Zhou, Min ^a   Shi, Guochao ^a   Wan, Huanying ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD); Administration and dosage; Chronic Obstructive Pulmonary Disease (COPD); Glucocorticoids; Meta analysis

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE;

ANXIETY DISORDER; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DELIRIUM; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPISTAXIS; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; GLUCOSURIA; HEARTBURN; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; MOOD CHANGE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY INFECTION; SEIZURE; SIDE EFFECT; SUPERINFECTION; TUBERCULOSIS; WEIGHT GAIN;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD); ADMINISTRATION AND DOSAGE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); GLUCOCORTICOIDS; META-ANALYSIS;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884817016     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12008     Document Type: Article

References (49)

1. Rabe KF, Hurd S, Anzueto A, etal. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
2. Mathers C, Fat DM, Boerma JT. The Global Burden of Disease: 2004 Update. Geneva, World Health Organization, 2008.
3. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Resp Crit Care. 1996;154(4): 959-967.
4. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. Chest. 1997;111(3): 732-743.
5. Walters J, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;1: Art. No. CD001288.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1): 1-12.
7. Deeks JJ, Higgins JPT, Altman DG. 9.4.5.2 Meta-analysis of change scores. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). John Wiley & Sons, Ltd, Hoboken, New Jersey, The Cochrane Collaboration, 2008. Available at: http://www.cochrane-handbook.org (accessed September 2008).
8. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11): 1539-1558.
9. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4): 1088-1101.
10. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Brit Med J. 1997;315(7109): 629-634.
11. Schimmer B, Parker K. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2001: 1649-1677.
12. Vondracek SF, Hemstreet BA. Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2006;63(7): 645-652.
13. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev, 2001(1): Art. No. CD001740.
14. Stallberg B, Selroos O, Vogelmeier C, Andersson E, Ekstrom T, Larsson K. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res. 2009;10: 11.
15. Chen G, Xie CM, Luo YF. The effects and therapeutic duration of oral corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary diseases. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31(8): 577-580.
16. Kunter E, Ilvan A, Ozmen N, Demirer E, Ozturk A, Avsar K, Sayan O, Kartaloglu Z. Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration. 2008;75(2): 145-154.
17. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, van den Berg JWK. Oral or IV prednisolone in the treatment of COPD exacerbations*. Chest. 2007;132(6): 1741-1747.
18. Ghanei M, Khalili ARH, Arab MJ, Mojtahedzadeh M, Aslani J, Lessan-Pezeshki M, Panahi Y, Alaeddini F. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol. 2005;97(5): 302-305.
19. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348(26): 2618-2625.
20. Li H, He G, Chu H, Zhao L, Yu H. A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD. Respirology. 2003;8(2): 199-204.
21. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease. A randomized controlled trial. Am J Resp Crit Care. 2002;165(5): 698-703.
22. Shortall SP, Blum J, Oldenburg FA, Rodgerson L, Branscombe JM, Harrow EM. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen. Respir Care. 2002;47(2): 154-158.
23. Sayner A, Aytemur ZA, Cirit M, Ünsal I. Systemic glucocorticoids in severe exacerbations of COPD*. Chest. 2001;119(3): 726-730.
24. Davies L, Angus RM, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177): 456-460.
25. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25): 1941-1947.
26. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Resp Crit Care. 1996;154(2): 407.
27. Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther. 1996;60(6): 675-678.
28. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction* 1. Am J Emerg Med. 1996;14(2): 139-143.
29. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest. 1989;95(3): 563-567.
30. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980;92(6): 753-758.
31. Eidani E, Sheikh A, Pour F, Jolodar A, Ahmadi G. The effect of oral corticosteroid on spirometric parameters in COPD patients induced by mustard gas. Eur Respir J. 2006;28(Suppl. 50): 216s [P1281]. [Abstract].
32. Ghanei M, Arab M, Hosseini A, Mojtahedzadeh M, Asiani J. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbations of mustard gas induced COPD. Eur Respir J. 26(Suppl. 49): Abstract No. 1980. [Abstract].
33. Rizzato G. Effects of deflazacort hemisuccinate vs. methylprednisolone succinate in COPD exacerbations. Internista. 1998;6(1): 35-40.
34. Rahman M, Rahman M, Mamun AA, Haque MDA. Role of 7-Day AND 14-Day Courses of Oral Prednisolone Treatment in Acute Exacerbation of COPD. Chest. 2004;126(Suppl. 4): 839S-a. [Abstract].
35. Alia I, Cal MA, Esteban A, etal. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med. 2011;171(21): 1939-1946.
36. Chen G, Xie C. The efficacy and treatment length of oral corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2005;26(Suppl. 49): Abstract No. 1966. [Abstract].
37. Wood-Baker R, Wilkinson J, Pearce M, Ryan G. A double-blind, randomised, placebo-controlled trial of corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Aust N Z J Med. 1998;28: 262. [Abstract].
38. Rostom R, Mink S, Hebert P, Cardinal P. The long term efficacy of methylprednisolone in the treatment of acute exacerbation of COPD. Chest. 1994;106(2): 161S.
39. De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, van den Berg JWK. A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD. Eur Respir J. 2004;24(Suppl. 48): 64s. [Abstract].
40. Gerogianni A, Mathioudakis G, Koulouris N, Orphanidou D, Malamos N, Markozannes E, Tzannes S, Jordanoglou J. The effect of oral steroid treatment in patients with chronic bronchitis. Am J Respir Crit Care. 165(Suppl. 8): A594.
41. Mirici A, Meral M, Akgun M, Tutar U. Comparison of the effectiveness of parenteral and nebuliser steroid in COPD exacerbations. Eur Respir J. 2002;20(Suppl. 38): 243s.
42. Willaert W, Daenen M, Bomans P, Verleden G, Decramer M. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J. 2002;19(5): 928-935.
43. Dahlén I, Janson C, Björnsson E, Stålenheim G, Peterson CGB, Venge P. Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respir Med. 2001;95(11): 891-897.
44. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD*. Chest. 2008;133(3): 756-766.
45. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. 2011. Available from: http://www.goldcopd.org/
46. Niewoehner DE, Erbland M, Collins D. Author response to: 'Kapur S, Kupfer Y, Tessler S.: glucocorticoids for chronic obstructive pulmonary disease. N Engl J Med. 1999;341(23): 1772-1773.
47. Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;346(13): 988-994.
48. Vondracek SF, Hemstreet BA. Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease? Pharmacotherapy. 2006;26(4): 522-532.
49. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23): 2359-2367.